EN
EN
Indications for the MLD Program: Specifically for the treatment of patients with metachromatic leukodystrophy (MLD) at all ages, including late-infantile, early-juvenile, and adult forms. MLD is a fatal rare genetic disease caused by ARSA gene mutations that result in a deficiency of arylsulfatase A (ARSA), leading to severe degeneration of the central and peripheral nervous systems; children usually lose the ability to walk and speak within a few years of onset and eventually die.Core mechanism of action: This is a foundational gene-modification therapy designed as a "single administration, potentially lifelong cure." First, CD34⁺ hematopoietic stem cells are harvested from the patient's bone marrow; ex vivo, a lentiviral vector is used to introduce a functional ARSA gene into the genome of these stem cells. The patient then receives myeloablative chemotherapy (to make room for the new cells), after which the gene-modified stem cells are reinfused. Once engrafted in the bone marrow, these stem cells differentiate into monocytes/macrophages, cross the blood-brain barrier into the central nervous system, differentiate into microglia, and continuously secrete the missing ARSA enzyme, thereby correcting the metabolic defect at its root.
This project aims to use cutting-edge directed cell differentiation technology to culture and differentiate diabetes-specific stem cells (code ZJ-K-0209) in vitro, fundamentally addressing the β-cell functional problem in patients with type 2 diabetes and achieving long-term, autonomous physiological blood glucose regulation. As a cell innovative drug targeting islet β-cell repair and microenvironment remodeling, it represents the most cutting-edge breakthrough in the fields of regenerative medicine and metabolic diseases today; compared with conventional insulin injection, its goal is to achieve a "functional cure" of diabetes.
Zhongjia Biotech's pipeline in the Alzheimer's disease (AD) field is highly innovative. Rather than using conventional antibody drugs or targeted gene-modified cells, it uses the body's own "special subtype natural killer (NK) cells" (code ZJ-S-0106) to intervene in this neurodegenerative disease.Technology route (non-gene-modified, allogeneic NK cells): This is an allogeneic, cryopreserved, non-gene-modified natural killer (NK) cell therapy. In brief, mononuclear cells are extracted from umbilical cord blood, expanded on a large scale and induced to differentiate in vitro using proprietary technology, and then these vigorous "special subtype NK cells" are infused intravenously back into patients.
Based on multi-omics cross-validation, this early precision detection platform for Alzheimer's disease relies on the innovative SERS-ML detection system, which effectively penetrates the complex background noise of biological samples and precisely captures subtle changes in molecular structure. Deep learning algorithms embedded in the system automatically and rapidly interpret complex spectral signals, eliminating errors caused by baseline drift, fluorescence interference and sample heterogeneity. Through machine learning-based intelligent adjustment of spectral features and noise suppression, the platform achieves precise quantification of core Alzheimer's biomarkers (such as p-Tau and Aβ42/40) at ultra-low concentrations from pM to fg/mL. This technology provides a breakthrough tool for ultra-early, non-invasive diagnosis and dynamic monitoring of AD, strongly driving the leap from laboratory testing to clinical precision medicine.